"Johnson & Johnson has been in China for nearly 40 years, and is a witness, participant, and beneficiary of China's great journey of reform and opening up." Song Weiqun, senior vice president of Johnson & Johnson and chairman of China, said. Since the reform and opening up, a large number of multinational companies have entered the Chinese market and have grown together with the Chinese economy. Recently, the reporter followed the report group of the online theme promotion activity of "New Era, New Opportunities - Multinational Enterprises in China", walked into a number of multinational enterprises with innovation centers and headquarters in Shanghai, and listened to their feelings about participating in China's innovation and development.
In 1985, Johnson & Johnson entered China and became the first batch of multinational companies to enter the Chinese market since the reform and opening up. Today, Johnson & Johnson has more than 10 legal entities in China, with supply chain bases located in Beijing, Shanghai, Guangzhou, Suzhou, Xi'an and other cities, with more than 10,000 employees. In June 2019, Johnson & Johnson settled JLABS, the world's largest and Asia-Pacific's first innovation incubator, in Zhangjiang, Shanghai. In 2021, Johnson & Johnson China will become the first open innovation platform certified by the Shanghai Municipal Government.
"The Chinese government has created a very good business environment for us, and we also feel the government's emphasis on innovative products." Song Weiqun, who had just returned from Boao, was interviewed by reporters at Johnson & Johnson's China headquarters in Xuhui District, Shanghai. He said, "We have a variety of ophthalmic products and future surgical robots that will be launched quickly through the 'New National Nine Articles' policy and local real-world data research. Last year, 55 innovative medical device products were approved for marketing, a year-on-year increase of 57.1% Among them, Johnson & Johnson’s innovative hemostatic product (Sujiya) accumulation particles are among them. In the field of pharmaceuticals, 30 of Johnson & Johnson’s 31 innovative drugs in China have been included in the National Medical Insurance Catalogue.”
With the same feelings as Johnson & Johnson, there is also Medtronic, a multinational company of the same age as China. It is precisely because of the emphasis on innovation and R&D in China that Medtronic, a leader in the medical technology industry, has established two innovation centers in China, located in Shanghai and Chengdu, which train about 15,000 medical professionals each year on average.
Founded in 2005, the Medtronic Innovation Center (Shanghai) is located in Caohejing Development Zone, Shanghai. It has world-leading clinical training facilities, including 2 DSA combined operating rooms, covering an area of 400 square meters, and can perform 11 surgical experiments at the same time. The clinical experiment layer, as well as the intensive care and anesthesia simulation training room, etc., provide an advanced clinical training and communication platform for medical staff in China and even Asia. The person in charge of the Medtronic Shanghai Innovation Center said, "This is not only a training center, but also a co-creation center. The front-line medical staff will share their practical experience, opinions and suggestions with our R&D personnel, and through continuous training, we will get the best solution for product development. "
"The first successful appearance of the world's smallest pacemaker was at the CIIE." As a "full attendance student" at the 5th CIIE, Gu Yushao, Senior Vice President of Medtronic and President of Greater China, introduced that the 5th CIIE In the expo, 60-70 world-leading innovative products are introduced in each session. Last year, with the help of the CIIE Bureau, the three major surgical robot platforms were brought to the Chinese market for the first time, and they shined brilliantly. "In the field of medical and health care, the Chinese market will definitely become the largest market in the world. Our current factory production and innovation center training in China are all serving the localization strategy. In the future, this will not only be a production base, but also a source of innovation," Gu Yushao explain.